Canadian Neuromuscular Disease Registry

The CNDR is actively recruiting individuals with ALS who are using or have used edaravone or amx0035. Currently, the CNDR is collaborating with clinicians, scientists, patient organizations, and industry on important studies to evaluate the safety, tolerability, and effectiveness of ALS therapies to support access to drugs for Canadians who may benefit.

The Canadian Neuromuscular Disease Registry (CNDR) is a national registry partnering with ALS clinics across the country aiming to improve access to care and therapies for people with ALS, and to increase the impacts of research in the Canadian healthcare system. The CNDR works with the community as valuable partners to provide essential clinical data related to people living with ALS. In order to participate, you will need to sign a form and agree for your physician to provide your medical information to the registry. Your privacy and security are always protected.

To join the CNDR community, please register here: www.cndr.org

University of Alberta Research Updates Dr. Wendy Johnston

Updated September 2022

Study of ANX005 in Adults with Amyotrophic Lateral Sclerosis (ALS)

A multi-center, open-label study of intravenous administration of ANX005 in patients with ALS.

Study Type: Therapeutic, Phase 2a

Status: Active & Recruiting

A Study to Evaluate Safety, Tolerability, Pharmacodynamic (PD) Markers, and Pharmacokinetics (PK) of AP-101 in Participants with Amyotrophic Lateral Sclerosis (ALS)

A multi-center, randomized, double-blind, and placebo-controlled study to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with familial and sporadic ALS.

Study Type: Therapeutic, Phase 2a

Status: Active & Recruiting

A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS) (COURAGE-ALS)

A multi-center, randomized, double-blind, and placebo-controlled trial of reldesemtiv to assess the effects on functional outcomes in patients with ALS.

Study Type: Therapeutic, Phase 3

Status: Active & Recruiting

Efficacy and Safety Study of Oral Edaravone Administered in Subjects with ALS

A multi-center, randomized, double-blind and placebo-controlled study to evaluate efficacy and safety of oral edaravone in subjects with ALS.

Study Type: Therapeutic, Phase 3

Status: Active & Recruiting

A Study to Investigate the Safety and Pharmacokinetics (PK) of ABBV-CLS-7262 in Patients with Amyotrophic Lateral Sclerosis

A multi-center, randomized, double-blind, and placebo-controlled study to assess safety, tolerability, and PK in patients with ALS following multiple doses of oral ABBV-CLS-7262 and an active treatment extension.

Study Type: Therapeutic, Phase 1

Status: Active & Recruiting

Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-Label Extension for 6 Months in Patients with ALS

A multi-center, randomized, double-blind, and placebo-controlled 12 month clinical trial followed by an open-label extension phase to evaluate the efficacy and safety of MN-166 in patients with ALS.

Study Type: Therapeutic, Phase 2b/3

Status: Active & Recruiting

For more information on the ongoing ALS projects at the University of Alberta visit https://sites.ualberta.ca/ALS/

University of Calgary Research Updates

Updated August 2021

Enrolling Clinical Drug Trial:

A Phase 3, Multi-center, double-blind, randomized, placebo-controlled trial to evaluate the efficacy and safety of reldesemtiv in patient with ALS Sponsor: Cytokinetics Trial Name: COURAGE-ALS

A Randomized, Double‑Blind, Placebo‑Controlled Study to Assess Safety, Tolerability, and Pharmacokinetics Following Multiple Doses of ABBV‑CLS‑7262 in Subjects with Amyotrophic Lateral Sclerosis Followed by an Active Treatment Extension

Sponsor: Calico Life Sciences

Phase: 1b

A Phase 2b/3, Multi-centre, randomized, double-blind, placebo-controlled, 12 month clinical trial to evaluate the efficacy and safety of MN-166 (Ibudilast) followed by an open-label extension in subjects with ALS

Sponsor: Medicinova Trial Name: COMBAT ALS

A Phase 3 Randomized, Placebo-Controlled Trial With a Longitudinal Natural History Run-In and Open-Label Extension to Evaluate BIIB067 Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation (ATLAS)

Sponsor: Biogen MA Inc

Trial Name: ATLAS

Staff Contacts:

Jose Martinez jamarti@ucalgary.ca 403-210-7009

Janet Petrillo japetril@ucalgary.ca 403-210-7006